Your browser doesn't support javascript.
loading
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.
Capdevila, Jaume; Bodei, Lisa; Davies, Philippa; Gorbounova, Vera; Jensen, Robert T; Knigge, Ulrich P; Krejs, Guenter J; Krenning, Eric; O'Connor, Juan Manuel; Peeters, Marc; Rindi, Guido; Salazar, Ramon; Vullierme, Marie-Pierre; Pavel, Marianne E.
Afiliação
  • Capdevila J; Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spainjcapdevila@vhio.net.
  • Bodei L; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Davies P; Neuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom.
  • Gorbounova V; Department of Oncology, Institution of Russian Academy of Medical Sciences, Moscow, Russian Federation.
  • Jensen RT; National Institutes of Health, Bethesda, Maryland, USA.
  • Knigge UP; Department of Surgery, University of Copenhagen, Copenhagen, Denmark.
  • Krejs GJ; Medical University of Graz, Graz, Austria.
  • Krenning E; Cyclotron Rotterdam BV, Erasmus MC, Rotterdam, The Netherlands.
  • O'Connor JM; Alexander Fleming Institute, Caba, Argentina.
  • Peeters M; Department of Oncology, Antwerp University Hospital, Antwerp, Belgium.
  • Rindi G; Fondazione Policlinico Universitario A. Gemelli IRCCS Roma-Università Cattolica del Sacro Cuore, Rome, Italy.
  • Salazar R; Catalan Institute of Oncology, Oncobell Program, IDIBELL, Cerca, Ciberonc, Barcelona, Spain.
  • Vullierme MP; Radiology Department, Beaujon Hôpital Assistance Publique, Paris, France.
  • Pavel ME; Friedrich-Alexander Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany.
Neuroendocrinology ; 108(1): 18-25, 2019.
Article em En | MEDLINE | ID: mdl-30153686
ABSTRACT
Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Tumores Neuroendócrinos / Pesquisa Biomédica / Neoplasias do Sistema Digestório / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Neuroendocrinology Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Tumores Neuroendócrinos / Pesquisa Biomédica / Neoplasias do Sistema Digestório / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Neuroendocrinology Ano de publicação: 2019 Tipo de documento: Article